Gestational Diabetes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major gestational diabetes markets are expected to exhibit a CAGR of 4.77% during 2024-2034.
The gestational diabetes market has been comprehensively analyzed in IMARC's new report titled "Gestational Diabetes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gestational diabetes refers to a type of diabetes that can occur in pregnant women. It develops when the body is unable to produce enough insulin to control the increased demand for glucose over that period. This results in high levels of glucose in the blood, which can lead to various complications for both the mother and the baby. Moreover, a pregnant woman with this ailment is at a higher risk of developing Type 2 diabetes later in life. Some of the common symptoms of gestational diabetes include frequent urination, increased thirst, blurred eyesight, genital itching, excessive tiredness, etc. The diagnosis of this ailment relies on a screening test during the second trimester or between 24 and 28 weeks of pregnancy. The healthcare provider may perform an initial glucose challenge test, followed by glucose tolerance testing to measure the blood sugar level and confirm a diagnosis among patients.
The increasing cases of hormonal changes during pregnancy that make the body less capable of processing blood sugar or utilizing insulin are primarily driving the gestational diabetes market. In addition to this, the rising incidences of multiple associated risk factors, such as being overweight, having a sedentary lifestyle, family history of diabetes, heart disease, etc., are also bolstering the market growth. Furthermore, the inflating utilization of effective anti-diabetic drugs, involving glibenclamide and metformin, to lower glucose concentrations in the blood and treat the underlying symptoms in patients, is acting as another significant growth-inducing factor. Apart from this, the escalating application of non-pharmacological interventions, like lifestyle modifications, which include eating a healthy and balanced diet, exercising regularly, maintaining optimum body weight, etc., is further creating a positive outlook for the market. Additionally, the growing popularity of insulin pens over conventional syringe therapies to treat this condition since they are more convenient to use, provide greater dose accuracy, stabilize blood sugar, and enhance patient outcomes is expected to drive the gestational diabetes market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the gestational diabetes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gestational diabetes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gestational diabetes market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the gestational diabetes market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the gestational diabetes market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current gestational diabetes marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the gestational diabetes market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the gestational diabetes market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the gestational diabetes market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of gestational diabetes across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of gestational diabetes by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of gestational diabetes by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with gestational diabetes across the seven major markets?
What is the size of the gestational diabetes patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of gestational diabetes?
What will be the growth rate of patients across the seven major markets?
Gestational Diabetes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for gestational diabetes drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gestational diabetes market?
What are the key regulatory events related to the gestational diabetes market?
What is the structure of clinical trial landscape by status related to the gestational diabetes market?
What is the structure of clinical trial landscape by phase related to the gestational diabetes market?
What is the structure of clinical trial landscape by route of administration related to the gestational diabetes market?
The gestational diabetes market has been comprehensively analyzed in IMARC's new report titled "Gestational Diabetes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gestational diabetes refers to a type of diabetes that can occur in pregnant women. It develops when the body is unable to produce enough insulin to control the increased demand for glucose over that period. This results in high levels of glucose in the blood, which can lead to various complications for both the mother and the baby. Moreover, a pregnant woman with this ailment is at a higher risk of developing Type 2 diabetes later in life. Some of the common symptoms of gestational diabetes include frequent urination, increased thirst, blurred eyesight, genital itching, excessive tiredness, etc. The diagnosis of this ailment relies on a screening test during the second trimester or between 24 and 28 weeks of pregnancy. The healthcare provider may perform an initial glucose challenge test, followed by glucose tolerance testing to measure the blood sugar level and confirm a diagnosis among patients.
The increasing cases of hormonal changes during pregnancy that make the body less capable of processing blood sugar or utilizing insulin are primarily driving the gestational diabetes market. In addition to this, the rising incidences of multiple associated risk factors, such as being overweight, having a sedentary lifestyle, family history of diabetes, heart disease, etc., are also bolstering the market growth. Furthermore, the inflating utilization of effective anti-diabetic drugs, involving glibenclamide and metformin, to lower glucose concentrations in the blood and treat the underlying symptoms in patients, is acting as another significant growth-inducing factor. Apart from this, the escalating application of non-pharmacological interventions, like lifestyle modifications, which include eating a healthy and balanced diet, exercising regularly, maintaining optimum body weight, etc., is further creating a positive outlook for the market. Additionally, the growing popularity of insulin pens over conventional syringe therapies to treat this condition since they are more convenient to use, provide greater dose accuracy, stabilize blood sugar, and enhance patient outcomes is expected to drive the gestational diabetes market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the gestational diabetes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gestational diabetes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gestational diabetes market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the gestational diabetes market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the gestational diabetes market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current gestational diabetes marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the gestational diabetes market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the gestational diabetes market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the gestational diabetes market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of gestational diabetes across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of gestational diabetes by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of gestational diabetes by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with gestational diabetes across the seven major markets?
What is the size of the gestational diabetes patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of gestational diabetes?
What will be the growth rate of patients across the seven major markets?
Gestational Diabetes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for gestational diabetes drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gestational diabetes market?
What are the key regulatory events related to the gestational diabetes market?
What is the structure of clinical trial landscape by status related to the gestational diabetes market?
What is the structure of clinical trial landscape by phase related to the gestational diabetes market?
What is the structure of clinical trial landscape by route of administration related to the gestational diabetes market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GESTATIONAL DIABETES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GESTATIONAL DIABETES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GESTATIONAL DIABETES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 GESTATIONAL DIABETES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GESTATIONAL DIABETES - UNMET NEEDS
10 GESTATIONAL DIABETES - KEY ENDPOINTS OF TREATMENT
11 GESTATIONAL DIABETES - MARKETED PRODUCTS
11.1 List of Gestational Diabetes Marketed Drugs Across the Top 7 Markets
11.1.1 Rinsulin (Human isophane insulin) - Geropharm
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 NovoLog (Insulin aspart) - Novo Nordisk
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GESTATIONAL DIABETES - PIPELINE DRUGS
12.1 List of Gestational Diabetes Pipeline Drugs Across the Top 7 Markets
12.1.1 Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GESTATIONAL DIABETES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GESTATIONAL DIABETES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GESTATIONAL DIABETES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Gestational Diabetes - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Gestational Diabetes - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Gestational Diabetes - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Gestational Diabetes - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Gestational Diabetes - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Gestational Diabetes - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Gestational Diabetes - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Gestational Diabetes - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Gestational Diabetes - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Gestational Diabetes - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Gestational Diabetes - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Gestational Diabetes - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Gestational Diabetes - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Gestational Diabetes - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Gestational Diabetes - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Gestational Diabetes - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Gestational Diabetes - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Gestational Diabetes - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Gestational Diabetes - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Gestational Diabetes - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Gestational Diabetes - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Gestational Diabetes - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Gestational Diabetes - Access and Reimbursement Overview
16 GESTATIONAL DIABETES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GESTATIONAL DIABETES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GESTATIONAL DIABETES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GESTATIONAL DIABETES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GESTATIONAL DIABETES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GESTATIONAL DIABETES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 GESTATIONAL DIABETES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GESTATIONAL DIABETES - UNMET NEEDS
10 GESTATIONAL DIABETES - KEY ENDPOINTS OF TREATMENT
11 GESTATIONAL DIABETES - MARKETED PRODUCTS
11.1 List of Gestational Diabetes Marketed Drugs Across the Top 7 Markets
11.1.1 Rinsulin (Human isophane insulin) - Geropharm
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 NovoLog (Insulin aspart) - Novo Nordisk
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GESTATIONAL DIABETES - PIPELINE DRUGS
12.1 List of Gestational Diabetes Pipeline Drugs Across the Top 7 Markets
12.1.1 Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GESTATIONAL DIABETES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GESTATIONAL DIABETES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GESTATIONAL DIABETES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Gestational Diabetes - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Gestational Diabetes - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Gestational Diabetes - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Gestational Diabetes - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Gestational Diabetes - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Gestational Diabetes - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Gestational Diabetes - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Gestational Diabetes - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Gestational Diabetes - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Gestational Diabetes - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Gestational Diabetes - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Gestational Diabetes - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Gestational Diabetes - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Gestational Diabetes - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Gestational Diabetes - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Gestational Diabetes - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Gestational Diabetes - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Gestational Diabetes - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Gestational Diabetes - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Gestational Diabetes - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Gestational Diabetes - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Gestational Diabetes - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Gestational Diabetes - Access and Reimbursement Overview
16 GESTATIONAL DIABETES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GESTATIONAL DIABETES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GESTATIONAL DIABETES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
